{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T12:49:33Z","timestamp":1793191773718,"version":"4.5.0"},"reference-count":38,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2025,9,2]],"date-time":"2025-09-02T00:00:00Z","timestamp":1756771200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2025,9,2]],"date-time":"2025-09-02T00:00:00Z","timestamp":1756771200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Haemophilia"],"published-print":{"date-parts":[[2025,11]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Despite factor (F)VIII prophylaxis, a perceived increased risk of bleeding for some people with severe haemophilia A (PwSHA) exists, limiting physical activity (PA) and restricting quality of life (QoL).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Aim<\/jats:title>\n                    <jats:p>HemiNorth 2 (EudraCT# 2020\u2010003256\u201032) is an interventional study evaluating the impact of switching from FVIII prophylaxis to emicizumab in PwSHA without FVIII inhibitors who have a need for improved prophylaxis in the Nordic countries.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Following completion of the HemiNorth non\u2010interventional study (NIS), eligible participants (aged \u2265 12\u201361 years) were enrolled in HemiNorth 2. The primary endpoint was health\u2010related QoL via the Comprehensive Assessment Tool for Challenges in Hemophilia (CATCH). Secondary endpoints included PA (International Physical Activity Questionnaire\u2010Short Form [IPAQ\u2010SF]), treatment preference (Emicizumab Preference [EmiPref] survey), joint health, model\u2010based annualised bleeding rates (ABRs) and adverse events.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Overall, 28 physically active male PwSHA were enrolled. Most baseline CATCH domains were \u2264 25 and remained consistent; mean treatment burden considerably improved from baseline for adults (\u221217.8) and adolescents (+16.7). IPAQ\u2010SF scores were consistent throughout the study. Overall, 23 of 25 (92.0%) EmiPref respondents preferred emicizumab over FVIII prophylaxis. Model\u2010based ABRs for treated bleeds decreased from 5.9 (95% confidence interval [CI]: 3.8\u20139.1) to 1.6 (95% CI: 0.9\u20133.0) from the NIS to HemiNorth 2, and participants with zero treated bleeds increased from 8 (28.6%) to 16 (57.1%). No new safety signals were reported.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Emicizumab improved treatment burden and was preferred by most participants over FVIII prophylaxis. PA levels were consistently high, and bleeding rates improved with emicizumab versus prior FVIII prophylaxis.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/hae.70121","type":"journal-article","created":{"date-parts":[[2025,9,3]],"date-time":"2025-09-03T10:40:49Z","timestamp":1756896049000},"page":"1271-1282","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Health\u2010Related Quality of Life, Physical Activity and Joint Health in People With Severe Haemophilia A Receiving Emicizumab: Results From the Phase IV HemiNorth 2 Study"],"prefix":"10.1111","volume":"31","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8500-2483","authenticated-orcid":false,"given":"Jan","family":"Astermark","sequence":"first","affiliation":[{"name":"Department of Translational Medicine Lund University  Malm\u00f6 Sweden"},{"name":"Department of Haematology Oncology and Radiation Physics Sk\u00e5ne University Hospital  Malm\u00f6 Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susanna","family":"Ranta","sequence":"additional","affiliation":[{"name":"Astrid Lindgren's Children's Hospital Karolinska University Hospital  Stockholm Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linda","family":"Myrin\u2010Westesson","sequence":"additional","affiliation":[{"name":"Region V\u00e4stra G\u00f6taland Department of Medicine Sahlgrenska University Hospital  Gothenburg Sweden"},{"name":"Sahlgrenska Academy Institution For Nursing Science and Health at Gothenburg University  Gothenburg Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marianne","family":"Hoffmann","sequence":"additional","affiliation":[{"name":"Department of Paediatrics and Adolescent Medicine University Hospital Rigshospitalet  Copenhagen Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandrine","family":"Quere","sequence":"additional","affiliation":[{"name":"F. Hoffmann\u2010La Roche Ltd  Basel Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amparo Yovanna Castro","family":"Sanchez","sequence":"additional","affiliation":[{"name":"Data Sciences, F. Hoffmann\u2010La Roche Ltd  Basel Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan","family":"Robson","sequence":"additional","affiliation":[{"name":"F. Hoffmann\u2010La Roche Ltd  Basel Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T\u00fcnde","family":"Czirok","sequence":"additional","affiliation":[{"name":"F. Hoffmann\u2010La Roche Ltd  Basel Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1911-3094","authenticated-orcid":false,"given":"Riitta","family":"Lassila","sequence":"additional","affiliation":[{"name":"Department of Haematology Coagulation Disorders Unit and Research Program Unit in Systems Oncology Oncosys Medical Faculty University of Helsinki  Helsinki Finland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P\u00e5l Andr\u00e9","family":"Holme","sequence":"additional","affiliation":[{"name":"Department of Haematology Oslo University Hospital  Oslo Norway"},{"name":"Institute of Clinical Medicine University of Oslo  Oslo Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2025,9,2]]},"reference":[{"key":"e_1_2_11_2_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2516.2007.01505.x"},{"key":"e_1_2_11_3_1","doi-asserted-by":"publisher","DOI":"10.1111\/hae.13862"},{"key":"e_1_2_11_4_1","doi-asserted-by":"publisher","DOI":"10.1111\/hae.14046"},{"key":"e_1_2_11_5_1","doi-asserted-by":"publisher","DOI":"10.1080\/17474086.2021.1924054"},{"key":"e_1_2_11_6_1","doi-asserted-by":"publisher","DOI":"10.1111\/hae.14641"},{"key":"e_1_2_11_7_1","doi-asserted-by":"publisher","DOI":"10.1111\/hae.14828"},{"key":"e_1_2_11_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(15)01123-X"},{"key":"e_1_2_11_9_1","unstructured":"F\u00f6rbundet Bl\u00f6darsjuka i Sverige.What Is It Like to Live With Hemophilia? Accessed February 2025 https:\/\/svlgcdn.blob.core.windows.net\/teamdata\/files\/43720\/Hur%20%C3%A4r%20det%20att%20leva%20med%20bl%C3%B6darsjuka%20en%20livskvalitetsunders%C3%B6kning.pdf."},{"key":"e_1_2_11_10_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-019-01200-2"},{"key":"e_1_2_11_11_1","doi-asserted-by":"publisher","DOI":"10.1160\/TH17-01-0030"},{"key":"e_1_2_11_12_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1703068"},{"key":"e_1_2_11_13_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2019001869"},{"key":"e_1_2_11_14_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1803550"},{"key":"e_1_2_11_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(19)30054-7"},{"key":"e_1_2_11_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(22)00377-5"},{"key":"e_1_2_11_17_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2023021832"},{"key":"e_1_2_11_18_1","doi-asserted-by":"publisher","DOI":"10.1002\/rth2.12837"},{"key":"e_1_2_11_19_1","doi-asserted-by":"publisher","DOI":"10.1111\/hae.14005"},{"key":"e_1_2_11_20_1","doi-asserted-by":"publisher","DOI":"10.1111\/hae.14762"},{"key":"e_1_2_11_21_1","doi-asserted-by":"publisher","DOI":"10.1111\/hae.14524"},{"key":"e_1_2_11_22_1","unstructured":"US Food and Drug Administration.HEMLIBRA\u00ae (Emicizumab\u2010kxwh) Injection for Subcutaneous Use Prescribing Information. Accessed June 2025 https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2024\/761083s018lbl.pdf."},{"key":"e_1_2_11_23_1","unstructured":"European Medicines Agency.HEMLIBRA\u00ae Solution for Injection: Emicizumab. [Initial EU approval: 2018]. Accessed February 2025 https:\/\/www.ema.europa.eu\/en\/documents\/product\u2010information\/hemlibra\u2010epar\u2010product\u2010information_en.pdf."},{"key":"e_1_2_11_24_1","unstructured":"Genentech Inc.HEMLIBRA\u00ae (Emicizumab\u2010kxwh) Injection for Subcutaneous Use Prescribing Information. Accessed February 2025 https:\/\/www.gene.com\/download\/pdf\/hemlibra_prescribing.pdf."},{"key":"e_1_2_11_25_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2209226"},{"key":"e_1_2_11_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2022.103678"},{"key":"e_1_2_11_27_1","doi-asserted-by":"publisher","DOI":"10.1002\/rth2.12670"},{"key":"e_1_2_11_28_1","doi-asserted-by":"publisher","DOI":"10.1111\/hae.14363"},{"key":"e_1_2_11_29_1","doi-asserted-by":"publisher","DOI":"10.1111\/hae.13618"},{"key":"e_1_2_11_30_1","doi-asserted-by":"publisher","DOI":"10.1111\/hae.14183"},{"issue":"2","key":"e_1_2_11_31_1","first-page":"363","article-title":"Non\u2010Interventional Study on Health\u2010Related Quality of Life, Physical Activity and Bleeds in Severe Non\u2010Inhibitor Hemophilia A Patients With a Bleeding Phenotype on FVIII Prophylaxis in the Nordics","volume":"8","author":"Bj\u00f6rkqvist J.","year":"2024","journal-title":"Research and Practice in Thrombosis and Haemostasis"},{"key":"e_1_2_11_32_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2022-157932"},{"key":"e_1_2_11_33_1","volume-title":"WHO Guidelines on Physical Activity and Sedentary Behaviour","author":"World Health Organization"},{"key":"e_1_2_11_34_1","doi-asserted-by":"publisher","DOI":"10.1111\/hae.14222"},{"key":"e_1_2_11_35_1","doi-asserted-by":"publisher","DOI":"10.1111\/hex.13404"},{"key":"e_1_2_11_36_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12185-023-03679-8"},{"key":"e_1_2_11_37_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2023-173073"},{"key":"e_1_2_11_38_1","doi-asserted-by":"publisher","DOI":"10.1111\/hae.14642"},{"key":"e_1_2_11_39_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2022-157249"}],"container-title":["Haemophilia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/hae.70121","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/hae.70121","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/hae.70121","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,8]],"date-time":"2026-03-08T20:38:00Z","timestamp":1773002280000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/hae.70121"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,2]]},"references-count":38,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["10.1111\/hae.70121"],"URL":"https:\/\/doi.org\/10.1111\/hae.70121","archive":["Portico"],"relation":{},"ISSN":["1351-8216","1365-2516"],"issn-type":[{"value":"1351-8216","type":"print"},{"value":"1365-2516","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,2]]},"assertion":[{"value":"2025-03-31","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-07-16","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-09-02","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}